如果一个靶点历经三十年才有一款药物成功上市,其成药难度之高,不言而喻。“研究这样的靶点如同攀登珠穆朗玛峰。”亚盛医药董事长、CEO(首席执行官)杨大俊在接受《每日经济新闻》记者采访时说。他和搭档王少萌从1995年开始研究Bcl-2靶点,在2004年筛选出化合物进入临床研究后,一做就是21年。今年7月,亚盛医药的利沙托克拉(利生妥)获得国家药品监督管理局附条件批准上市,成为国产原研首家、全球第2款...
Source Link如果一个靶点历经三十年才有一款药物成功上市,其成药难度之高,不言而喻。“研究这样的靶点如同攀登珠穆朗玛峰。”亚盛医药董事长、CEO(首席执行官)杨大俊在接受《每日经济新闻》记者采访时说。他和搭档王少萌从1995年开始研究Bcl-2靶点,在2004年筛选出化合物进入临床研究后,一做就是21年。今年7月,亚盛医药的利沙托克拉(利生妥)获得国家药品监督管理局附条件批准上市,成为国产原研首家、全球第2款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.